Efficacy and safety of mitazalimab in combination with mFOLFIRINOX in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): An interim analysis of the optimize-1 phase 1b/2 study

被引：0
|
作者：
Prenen, Hans
Borbath, Ivan
Paula Geboes, Karen
Alexandre Cassier, Philippe
Lambert, Aurelien
Mitry, Emmanuel
Macarulla, Teresa
Taieb, Julien
Blanc, Jean-Frederic
Feliu Batlle, Jaime
Rodriguez Garrote, Mercedes
Pazo Cid, Roberto A.
Valladares-Ayerbes, Manuel
Nordbladh, Karin
Enell Smith, Karin
Ellmark, Peter
Carlsson, Malin
Pico de Coana, Yago
Vijay Ambarkhane, Sumeet
Van Laethem, Jean-Luc
机构：
[1] Univ Antwerp, Ctr Oncol Res CORE, Integrated Personalized & Precis Oncol Network IP, Antwerp, Belgium
[2] Clin Univ St Luc, Woluwe St Lambert, Belgium
[3] Ghent Univ Hosp, Div Digest Oncol, Dept Gastroenterol, Ghent, Belgium
[4] Ctr Leon Berard, Lyon, France
[5] Inst Cancerol Lorraine, Vandoeuvre Les Nancy, France
[6] Inst Paoli Calmettes, Marseille, France
[7] Vall DHebron Univ Hosp, Vall DHebron Inst Oncol VHIO, Barcelona, Spain
[8] Georges Pompidou European Hosp, Paris, France
[9] CHU Bordeaux, Hop Haut Leveque, Serv Hepato Gastroenterol & Oncol Digest, Bordeaux, France
[10] Hosp Univ La Paz, Madrid, Spain
[11] Hosp Univ Ramon y Cajal, Madrid, Spain
[12] Hosp Univ Servet, Zaragoza, Spain
[13] Virgen Rocio Univ Hosp, Seville, Spain
[14] Alligator Biosci AB, Lund, Sweden
[15] Univ Libre Bruxelles, Hop Erasme, Brussels, Belgium
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4139
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Decreased appetite (DA) at baseline impacts prognosis in the NAPOLI-1 phase 3 study in metastatic pancreatic ductal adenocarcinoma (mPDAC)
    Lee, K.
    Bodoky, G.
    Blanc, J.
    Siveke, J.
    Macarulla Mercade, T.
    Wang-Gillam, A.
    Chen, L.
    Mirakhur, B.
    Chen, J.
    de Jong, F.
    ANNALS OF ONCOLOGY, 2018, 29
  • [22] A Phase 1B/2 trial of second line immunotherapy with pepinemab and avelumab for patients with metastatic pancreatic adenocarcinoma
    Ruffolo, Luis I.
    Byrne, Matthew
    Hilty, Bailey
    Belt, Brian A.
    Dave, Yatee
    Burchard, Paul
    Fisher, Terrence
    Evans, Elizabeth E.
    Mallow, Crystal
    Boise, Megan
    Carpizo, Darren
    Yeh, Jen Jen
    Linehan, David C.
    Mulkerin, Daniel
    CANCER RESEARCH, 2024, 84 (17)
  • [23] Phase 1b study of galunisertib in combination with gemcitabine in Japanese patients with metastatic or locally advanced pancreatic cancer
    Ikeda, Masafumi
    Takahashi, Hideaki
    Kondo, Shunsuke
    Lahn, Michael Mauritius Fabio
    Ogasawara, Ken
    Benhadji, Karim A.
    Fujii, Hisaki
    Ueno, Hideki
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2017, 79 (06) : 1169 - 1177
  • [24] Phase 1b study of galunisertib in combination with gemcitabine in Japanese patients with metastatic or locally advanced pancreatic cancer
    Masafumi Ikeda
    Hideaki Takahashi
    Shunsuke Kondo
    Michael Mauritius Fabio Lahn
    Ken Ogasawara
    Karim A. Benhadji
    Hisaki Fujii
    Hideki Ueno
    Cancer Chemotherapy and Pharmacology, 2017, 79 : 1169 - 1177
  • [25] RAMP 205: A phase 1b/2a study of gemcitabine, nab-paclitaxel, avutometinib, and defactinib in untreated metastatic pancreatic ductal adenocarcinoma
    Lim, Kian-Haut
    Hidalgo, Manuel
    O'Hara, Mark H.
    Spencer, Kristen R.
    Garrido-Laguna, Ignacio
    DeNardo, David G.
    Bhambhani, Vijeta
    Patrick, Gloria
    Cheng, Yaofeng
    Coma, Silvia
    Pachter, Jonathan A.
    Denis, Louis J.
    CANCER RESEARCH, 2024, 84 (02)
  • [26] A phase 1b study of OXIRI in pancreatic adenocarcinoma patients and its immunomodulatory effects
    Ng, Matthew
    Chen, Sylvia
    Ong, Whee Sze
    Balachander, Akhila
    Seet, Amanda
    Yeong, Joe
    Sutiman, Natalia
    Lim, Tony Kiat Hon
    Lee, Bernett
    Guo, Yu Amanda
    Leong, Wai Fook
    Lee, Sze Sing
    Lam, Justina
    Choo, Su Pin
    Skanderup, Anders Jacobsen
    Biswas, Subhra Kumar
    Tai, David
    Chowbay, Balram
    INTERNATIONAL JOURNAL OF CANCER, 2022, 151 (03) : 435 - 449
  • [27] Updated results of a phase 1b/2 study of surufatinib plus camrelizumab, nab-paclitaxel and S-1 (NASCA) as first-line therapy for metastatic pancreatic adenocarcinoma (mPDAC).
    Jia, Ru
    Si, Hai-Yan
    Wang, Zhi-Kuan
    Deng, Guo-Chao
    Zhang, Nan
    Liu, Fang-Fang
    Shi, Yue
    Zhang, Yao-Yue
    Jia, Yu-Shan
    Wang, Yanrong
    Fan, Meng-Jiao
    Miao, Meng-Meng
    Zhang, Bei
    Tong, Shuang
    Dai, Guang-Hai
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 671 - 671
  • [28] A phase 1/2 study to evaluate the safety, tolerability, and preliminary efficacy of GP-2250 in combination with gemcitabine for advanced or metastatic pancreatic adenocarcinoma
    Kasi, Anup
    Iglesias, Jose Luis
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [29] Prognostic value of baseline biliary stents on outcomes in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) in the NAPOLI-1 trial
    Lakatos, G.
    Lee, K.
    Siveke, J.
    Blanc, J.
    Macarulla Mercadé, T.
    Dean, A.
    Bodoky, G.
    Mirakhur, B.
    Chen, J.
    Wang-Gillam, A.
    Chen, L.
    de Jong, F.
    ANNALS OF ONCOLOGY, 2018, 29 : 42 - 42
  • [30] A phase 1b/2 trial of pepinemab and avelumab as second line therapy for patients with metastatic pancreatic adenocarcinoma.
    Hilty, Bailey
    Ruffolo, Luis I.
    Belt, Brian A.
    Byrne, Matthew
    Dave, Yatee A.
    Burchard, Paul R.
    Fisher, Terrence Lee
    Evans, Elizabeth E.
    Mallow, Crystal L.
    Boise, Megan
    Zauderer, Maurice
    Mulkerin, Daniel
    Yeh, Jen Jen
    Linehan, David
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : TPS712 - TPS712
12345